EVolution of a patiEnt-REported Symptom-based Risk Stratification sySTem to Redesign the Suspected Head and Neck Cancer Referral Pathway (Phase 1)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 165
- Locations
- 4
- Primary Endpoint
- Inventory and specification for the SYmptom iNput Clinical (SYNC) system
Study Overview
Brief Summary
Can a patient-reported symptom-based risk stratification system improve the suspected head and neck cancer (HNC) pathway?
Our methodology includes six interlinked work packages to deliver our aim, with EVEREST-HN 1 encompassing the first of these and seeking to optimise a patient-reported symptom inventory for HNC and outline requirement specification for the SYmptom iNput Clinical (SYNC) system.
Detailed Description
The EVEREST-HN pathway should be based on a comprehensive understanding of existing HNC diagnostic pathways and what patients and clinicians value in these. The language used within the EVEREST pathway needs to be accessible and optimal to elicit appropriate information.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adults ≥ 18 years referred via suspected HNC pathway without previous history of HNC
- •Participants willing and able to give informed consent for participation in the study.
- •Clinicians:
- •Staff at participating sites involved in the diagnostic pathway for people with suspected HNC.
Exclusion Criteria
- •Individuals who do not meet the inclusion criteria.
Outcomes
Primary Outcomes
Inventory and specification for the SYmptom iNput Clinical (SYNC) system
Time Frame: September 2022 - August 2023
To optimise a patient-reported symptom inventory for HNC and outline requirement specification for the SYmptom iNput Clinical (SYNC) system
Secondary Outcomes
- To further explore the current suspected HNC pathway and the language used when discussing symptoms.(September 2022 - August 2023)